The tumor samples in the historical cohorts were selected randomly based on the cases reported to the Finnish Cancer Registry, and nearly all tumors (91.8%) were analyzed for the newest cohort (2004 to 2005), so these figures were used to estimate the incidence trends of HER-2-positive breast cancer in the population. The gene discussed is ERBB2; the disease is breast carcinoma.